<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425568</url>
  </required_header>
  <id_info>
    <org_study_id>DIR1-SLGSC</org_study_id>
    <nct_id>NCT00425568</nct_id>
  </id_info>
  <brief_title>Transdermal Testosterone Gel/Effect on Erection Quality as Measured by DIR</brief_title>
  <official_title>Phase I Study of Transdermal Testosterone Gel and Its Effect on Erection Quality as Measured by a Digital Inflection Rigidometer (DIR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lamm, Steven, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lamm, Steven, M.D.</source>
  <brief_summary>
    <textblock>
      Low testosterone may be responsible for &quot;soft&quot; erections in men. The purpose of our study is
      to see whether the daily application of a testosterone gel to raise testosterone levels will
      also increase the &quot;hardness&quot; of a man's erection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Hypogonadism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AndroGel (Transdermal Testosterone Gel)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Testosterone &lt;350 ng/dL,

          -  21-59 years of age,

          -  BMI &lt;30

        Exclusion Criteria:

          -  Those with carcinoma of the breast or known or suspected carcinoma of the prostate or
             with known hypersensitivity to any of the ingredients in AndroGel.

          -  Men will be excluded if they have unstable angina, hypertension, diabetes, heart
             failure, or coronary artery disease.

          -  Men will agree to discontinue use of current testosterone replacement, as well as
             Viagra or any other PDE5 inhibitors for 30 days.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Lamm, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Steven Lamm, M.D.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>January 20, 2007</study_first_submitted>
  <study_first_submitted_qc>January 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2007</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <keyword>hypogonadism</keyword>
  <keyword>low testosterone level</keyword>
  <keyword>gonadal deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

